Stem cells

Pluripotent stem cells
#Human disease models #iPSC #Liver disease #Preclinical investigations #Stem cells #Webinar

iPSC derived cells for developing drug and gene therapies

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models… Read More

Webinar date:
Supported by DefiniGEN
#News

Stem cells
#Human disease models #iPSC #Liver disease #Preclinical investigations #Stem cells #Webinar

How can iPSC derived cells can be used to support drug development?

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models… Read More

Webinar date:
Supported by DefiniGEN
#News

#Artificial intelligence (AI) #Breast cancer #Head and neck cancer #Immunotherapy #Long Covid #Monoclonal antibodies #Oncology #Parkinson's #Stem cells

New DDW Highlights podcast out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for… Read More

#News

#Artificial intelligence (AI) #Breast cancer #Head and neck cancer #Immunotherapy #Long Covid #Monoclonal antibodies #Oncology #Parkinson's #Stem cells

This week in drug discovery (28 August – 1 September)  

News round-up for 28 August – 1 September by DDW Digital Content Editor Diana Spencer. This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for head and neck cancer, an estrogen receptor degrader for breast cancer, a mitochondrial activator for long Covid,… Read More

#News

Thymus
#Cancer research #Francis Crick Institute #Immune response #Stem cells #T cell activation

Researchers reveal regenerative potential of the thymus

Researchers have identified stem cells in the human thymus for the first time, representing a potential new target to understand immune diseases and cancer. The thymus is a gland located in the front part of the chest, the place where thymocytes (the cells in the thymus)… Read More

#News #Trending News

Degeneration of dopaminergic neuron in Parkinson's disease
#Bayer #BlueRock Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's #Stem cells

Stem cell derived Parkinson’s therapy shows promise

A stem cell derived investigational therapy for treating Parkinson’s disease has shown promise in early clinical trials. BlueRock Therapeutics, a subsidiary of Bayer, has announced details of the positive data from a Phase I clinical trial for bemdaneprocel (BRT-DA01). The data were presented at… Read More

#News #Trending News

Pluripotent stem cells
#Human disease models #iPSC #Liver disease #Preclinical investigations #Stem cells #Webinar

How do iPSC derived cells support development of gene therapies?

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models… Read More

Webinar date:
Supported by DefiniGEN
#News

Pluripotent stem cells
#Human disease models #iPSC #Liver disease #Preclinical investigations #Stem cells #Webinar

Discover how iPSC derived cells can be used to support the development of drug and gene therapies

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models to simulate… Read More

Webinar date:
Supported by DefiniGEN
#Webinars

Heart health concept
#Drug discovery #Heart attack #Regenerative Medicine #Stem cells #Turning Science into Business

Turning Science into Business: Can regenerative medicine treat heart attacks?   

DDW’s Reece Armstrong speaks to Hendrik Streefkerk, Chief Medical Officer and Drug Safety Officer of CellProthera about the company’s cell therapy for acute myocardial infarction (AMI) and why regenerative medicine could be key to treating cardiac diseases.   Based in France, CellProthera is a small, regenerative cell therapy developer that… Read More

#Exclusive Content

Gene editing
#bit bio #CRISPR #Drug discovery #Stem cells #Synthetic biology #Synthetic DNA

Synthetic biology: Impacting drug discovery

Listen to this article on the DDW Podcast: Mark Kotter, Founder and CEO of bit.bio, talks with Reece Armstrong about different approaches to synthetic biology and its applications in programming stem cells into mature, functional human cells for drug discovery and the creation of next generation. In the last 10 years,… Read More

#Exclusive Content

Microglia
#bit bio #iPSC #Poster #Stem cells

Poster: Accelerated production of functional microglia

Download this new scientific Poster from bit.bio, just revealed at ISSCR 2023. You will discover: How precision reprogramming generates consistent, functional human microglia (ioMicroglia) from iPSCs in just 10 days Independent validation that ioMicroglia undergo phagocytosis of both E. coli particles and amyloid beta particles Independent validation… Read More

#News

#iPSC #Poster #Stem cells

Accelerated production of functional microglia from reprogrammed hiPSCs

In this scientific Poster, just revealed at ISSCR 2023, you will discover: How precision reprogramming generates consistent, functional human microglia (ioMicroglia) from iPSCs in just 10 days Independent validation that ioMicroglia undergo phagocytosis of both E. coli particles and amyloid beta particles Independent validation that ioMicroglia show… Read More

#Resources

Medical researchers
#Human disease models #Humanised Immune System (HIS) #Stem cells #The Jackson Laboratory

Which immune-humanized platform is right for my application?

Humanization of highly immunodeficient NSG mice with hematopoietic stem cells or peripheral blood mononuclear cells provides a powerful platform for very precise modeling of human immune responses. These immune-humanized platforms enable researchers to test a wide range of human-specific therapeutic approaches developed to either up or down regulate… Read More

Webinar date:
Brought to you by The Jackson Laboratory
#News

#Charles River #Drug discovery #Gene therapy #Human disease models #Immunotherapy #iPSC #Regenerative Medicine #Stem cells

Stem cells’ versatility in drug development  

This article is sponsored by Charles River. Research tools, safety testing and regenerative medicines – these endless stem cell applications are powering precision, speed, and new modalities in drug development.     Stem cells for use in drug discovery Stem cells are fast becoming an invaluable tool in the drug… Read More

#News

Scientist in laboratory
#Human disease models #Humanised Immune System (HIS) #Stem cells #The Jackson Laboratory

Webinar: How to choose the right immune-humanized platform

Humanization of highly immunodeficient NSG mice with hematopoietic stem cells or peripheral blood mononuclear cells provides a powerful platform for very precise modeling of human immune responses. These immune-humanized platforms enable researchers to test a wide range of human-specific therapeutic approaches developed to either up or down regulate… Read More

Webinar date:
Brought to you by The Jackson Laboratory
#News

Scientist in laboratory
#Human disease models #Humanised Immune System (HIS) #Stem cells #The Jackson Laboratory

Exclusive event: How to compare immune-humanized platforms

Humanization of highly immunodeficient NSG mice with hematopoietic stem cells or peripheral blood mononuclear cells provides a powerful platform for very precise modeling of human immune responses. These immune-humanized platforms enable researchers to test a wide range of human-specific therapeutic approaches developed to either up or down regulate… Read More

Webinar date:
Brought to you by The Jackson Laboratory
#News